CurrentEndo
Get Weekly

Endocrinology journalCurrentEndo coverage

The Lancet Diabetes & Endocrinology

What CurrentEndo has captured from this journal. The coverage figures describe CurrentEndo's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentEndo holds 186 Briefs from The Lancet Diabetes & Endocrinology, most often randomized controlled trials and cohort studies.

Recent
6 Briefs
past 90 days
Archive
186 Briefs
research published from January 2023 to today · 14 undated
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 186 Briefs CurrentEndo has covered from Lancet Diabetes Endocrinol, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from The Lancet Diabetes & Endocrinology

All coverage, newest first

  1. Lancet Diabetes Endocrinol

    Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study

    Cross-sectional studyT2D & other

  2. Lancet Diabetes Endocrinol

    Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial

    Randomized controlled trialObesity

  3. Lancet Diabetes Endocrinol

    Disease modification outcomes in type 2 diabetes: a modified Delphi

    Guideline or statementT2D & other

  4. Lancet Diabetes Endocrinol

    Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case–control study

    Cohort studyComplications

  5. Lancet Diabetes Endocrinol

    Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial

    Randomized controlled trialObesity

  6. Lancet Diabetes Endocrinol

    Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

    Randomized controlled trialT2D & other

  7. Lancet Diabetes Endocrinol

    Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

    Randomized controlled trialT2D & other

  8. Lancet Diabetes Endocrinol

    Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial

    Randomized controlled trialObesity

  9. Lancet Diabetes Endocrinol

    Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis

    Meta-analysisComplications

  10. Lancet Diabetes Endocrinol

    Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement

    Guideline or statementObesity

  11. Lancet Diabetes Endocrinol

    Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study

    Cohort studyAdrenal

  12. Lancet Diabetes Endocrinol

    Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial

    Randomized controlled trialT1D

  13. Lancet Diabetes Endocrinol

    Whole-population trends in obesity across dimensions of inequality in England, 2019–25: a retrospective, longitudinal cohort study of 54 million adults

    Cohort studyObesity

  14. Lancet Diabetes Endocrinol

    1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study

    Cohort studyObesity

  15. Lancet Diabetes Endocrinol

    Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

    Randomized controlled trialT2D & other

  16. Lancet Diabetes Endocrinol

    Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

    Randomized controlled trialT2D & other

  17. Lancet Diabetes Endocrinol

    Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial

    Randomized controlled trialT2D & other

  18. Lancet Diabetes Endocrinol

    Type 1 diabetes intervention clusters in resource-limited settings: a systematic review and economic evaluation

    Meta-analysisT1D

  19. Lancet Diabetes Endocrinol

    A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial

    Secondary analysisComplications

  20. Lancet Diabetes Endocrinol

    Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study

    Cohort studyAdrenal

  21. Lancet Diabetes Endocrinol

    Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study

    Cohort studyComplications

  22. Lancet Diabetes Endocrinol

    Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies

    Cohort studyThyroid

  23. Lancet Diabetes Endocrinol

    Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries

    Meta-analysisT2D & other

  24. Lancet Diabetes Endocrinol

    Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study

    Randomized controlled trialBone & mineral

  25. Lancet Diabetes Endocrinol

    Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial

    Randomized controlled trialTechnology

  26. Lancet Diabetes Endocrinol

    Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

    Randomized controlled trialObesity

  27. Lancet Diabetes Endocrinol

    Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study

    Cohort studyT1D

  28. Lancet Diabetes Endocrinol

    Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based study

    Cohort studyComplications

  29. Lancet Diabetes Endocrinol

    Risk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study

    Cohort studyPituitary

  30. Lancet Diabetes Endocrinol

    Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study

    Cohort studyT2D & other

  31. Lancet Diabetes Endocrinol

    Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial

    Randomized controlled trialTechnology

  32. Lancet Diabetes Endocrinol

    Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

    Randomized controlled trialAdrenal

  33. Lancet Diabetes Endocrinol

    3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial

    Randomized controlled trialBone & mineral

  34. Lancet Diabetes Endocrinol

    Temporal changes and genetic susceptibility to type 2 diabetes (1984–2019; HUNT): a longitudinal, population-based study

    Cohort studyT2D & other

  35. Lancet Diabetes Endocrinol

    Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial

    Randomized controlled trialLipids & liver

  36. Lancet Diabetes Endocrinol

    Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study

    Cohort studyAdrenal

  37. Lancet Diabetes Endocrinol

    Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology

    Guideline or statementTechnology

  38. Lancet Diabetes Endocrinol

    Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

    Randomized controlled trialLipids & liver

  39. Lancet Diabetes Endocrinol

    Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement

    Guideline or statementTechnology

  40. Lancet Diabetes Endocrinol

    11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050

    Research articleT2D & other

All 186 Briefs in ExploreShowing the 40 most recently published